Intravitreal ranibizumab shows disease regression in retinopathy of prematurity, suggesting reduced therapy needs.
To determine the effect of intravitreal ranibizumab (IVR) in patients with treatment-naïve retinopathy of prematurity (ROP) in terms of disease regression and need for rescue therapy.
No takes yet. Share an insight, caveat, or question.
Khalid et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: